background: bleeding events in hemophilic patients with inhibitors are managed by bypassing agents. currently available agents in iran are recombinant activated factor vii (rfviia; aryogen, aryoseven) and feiba (factor eight inhibitor bypassing agent). no standardized and accurate assay is currently available for monitoring the effectiveness of bypassing agents. we suggested that history of the...

bypassing agents are the most commonly used medicines for the treatment of hemophilia patients with inhibitors. the aim of this study is to identify the cost components of management of bleeding vents in hemophilia patients with inhibitors in iran. this study is a cross-sectional study using a bottom-up approach to determine the cost components of treatment of hemophilia patients with inhibitor...

Bypassing agents are the most commonly used medicines for the treatment of hemophilia patients with inhibitors. The aim of this study is to identify the cost components of management of bleeding vents in hemophilia patients with inhibitors in Iran. This study is a cross-sectional study using a bottom-up approach to determine the cost components of treatment of hemophilia patients with inh...

background: among diverse protein purification systems, affinity chromatography is the most attractive one in the purification process of coagulation factors. coagulation factor vii is a plasma serine protease that has a significant role in natural human hemostasis and its recombinant form such as aryoseventm, has been applied in clinical treatment of bleeding disorders. immunoaffinity chromato...

Eptacog alfa (NovoSeven®) is a vitamin K-dependent recombinant Factor VIIa produced by genetic engineering from baby hamster kidney (BHK) cells as a single peptide chain of 406 residues. After activation, it consists of a light chain (LC) of 152 amino and a heavy chain (HC) of 254 amino acids. Recombinant FVIIa undergoes many post-translational modifications (PTMs). The first ten glutamic acids...

BACKGROUND Postoperative bleeding after cardiac reoperations is among the most complicating problems, both for the physicians and for the patients. Many modalities have been used to decrease its adverse effects and the need for blood products administration. OBJECTIVES In a randomized double-blinded clinical trial of redo cardiac valve surgery in adult, the effect of active recombinant factor...

conclusions our study demonstrated the efficacy of rfviia in controlling postoperative bleeding in redo cardiac valve surgeries regarding subsequent blood loss and transfusion requirement; however, outcome results remains to be defined. results study groups showed no difference regarding baseline variables. three patients in rfviia group (16.67%) and 13 in placebo group (72.23%) received blood ...